MIST
NASDAQ · Pharmaceuticals
Milestone Pharmaceuticals In
$0.76
+0.07 (+10.15%)
Financial Highlights (FY 2026)
Revenue
2.30M
Net Income
-94,053,501
Gross Margin
—
Profit Margin
-4,078.8%
Rev Growth
-32.4%
D/E Ratio
1.37
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 39.6% | 39.6% |
| Operating Margin | -4,019.4% | -3,617.5% | 42.8% | 46.2% |
| Profit Margin | -4,078.8% | -3,874.8% | 30.7% | 34.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.30M | 3.40M | 19.07M | 23.97M |
| Gross Profit | — | — | 7.56M | 9.49M |
| Operating Income | -92,535,712 | -123,161,994 | 8.16M | 11.07M |
| Net Income | -94,053,501 | -125,182,122 | 5.86M | 8.22M |
| Gross Margin | — | — | 39.6% | 39.6% |
| Operating Margin | -4,019.4% | -3,617.5% | 42.8% | 46.2% |
| Profit Margin | -4,078.8% | -3,874.8% | 30.7% | 34.3% |
| Rev Growth | -32.4% | -32.4% | +19.4% | -5.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 26.37M | 26.37M | 58.80M | 47.90M |
| Total Equity | 19.26M | 19.26M | 104.63M | 96.86M |
| D/E Ratio | 1.37 | 1.37 | 0.56 | 0.49 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -92,514,512 | -129,974,543 | 12.52M | 14.11M |
| Free Cash Flow | — | — | 4.46M | 4.28M |